Halozyme Therapeutics, Inc. (HALO)
Largest Insider Buys in Sector
HALO Stock Price History Chart
HALO Stock Performance
About Halozyme Therapeutics, Inc.
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. Its flagship product is Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in subcutaneous urography and to improve resorption of radiopaque agents. The company also develops Perjeta; RITUXAN HYCELA and MabThera SC for the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL); RITUXAN SC for patients with CLL; and HYQVIA for the treatment of immunodeficiency disorders. In addition, it is developing Tecentriq for non-small cell lung cancer; OCREVUS for multiple sclerosis; DARZALEX for the treatment of patients with amyloidosis, smoldering myeloma, and multiple myeloma; nivolumab for the treatment of solid tumors; ARGX-113, a human neonatal Fc receptor; ARGX-117 to treat autoimmune diseases; and BMS-986179, an anti-CD-73 antibody. The company has collaborations with F. Hoffmann-La Roche, Ltd.; Hoffmann-La Roche, Inc.; Baxalta US Inc.; Baxalta GmbH; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol-Myers Squibb Company; Alexion Pharma Holding; ARGENX BVBA; Horizon Therapeutics plc; National Institute of Allergy and Infectious Diseases; Centre for the AIDS Programme of Research in South Africa; and ViiV Healthcare Limited for small and large molecule targets for the treatment and prevention of HIV. Halozyme Therapeutics, Inc. was founded in 1998 and is based in San Diego, California.
Insider Activity of Halozyme Therapeutics, Inc.
Over the last 12 months, insiders at Halozyme Therapeutics, Inc. have bought $0 and sold $20.39M worth of Halozyme Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Halozyme Therapeutics, Inc. have bought $748,697 and sold $16.34M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 52,629 shares for transaction amount of $748,697 was made by Kelley Kenneth J (director) on 2020‑03‑19.
List of Insider Buy and Sell Transactions, Halozyme Therapeutics, Inc.
| 2024-10-16 | Sale | SVP, CHIEF TECHNICAL OFFICER | 10,000 0.0074% | $53.26 | $532,590 | -5.41% | ||
| 2024-10-15 | Sale | SVP, CHIEF TECHNICAL OFFICER | 10,000 0.0075% | $53.75 | $537,469 | -6.02% | ||
| 2024-10-09 | Sale | PRESIDENT AND CEO | 10,000 0.0073% | $52.58 | $525,783 | +1.08% | ||
| 2024-10-08 | Sale | PRESIDENT AND CEO | 10,000 0.0075% | $54.00 | $539,961 | -6.41% | ||
| 2024-09-26 | Sale | PRESIDENT AND CEO | 10,000 0.0076% | $56.10 | $560,970 | +1.52% | ||
| 2024-09-25 | Sale | PRESIDENT AND CEO | 10,000 0.0076% | $56.34 | $563,370 | +1.09% | ||
| 2024-09-24 | Sale | PRESIDENT AND CEO | 10,000 0.0079% | $58.21 | $582,100 | -2.16% | ||
| 2024-09-18 | Sale | SVP, CHIEF TECHNICAL OFFICER | 10,000 0.0079% | $62.03 | $620,316 | -14.57% | ||
| 2024-09-17 | Sale | SVP, CHIEF TECHNICAL OFFICER | 10,000 0.008% | $62.88 | $628,780 | -13.68% | ||
| 2024-09-12 | Sale | PRESIDENT AND CEO | 10,000 0.0077% | $59.20 | $592,030 | -11.08% | ||
| 2024-09-11 | Sale | PRESIDENT AND CEO | 10,000 0.0079% | $59.09 | $590,870 | +2.46% | ||
| 2024-09-10 | Sale | PRESIDENT AND CEO | 10,000 0.0079% | $59.09 | $590,890 | -9.13% | ||
| 2024-08-21 | Sale | SVP, CHIEF TECHNICAL OFFICER | 10,000 0.0078% | $61.75 | $617,470 | -7.19% | ||
| 2024-08-20 | Sale | SVP, CHIEF TECHNICAL OFFICER | 10,000 0.0079% | $61.05 | $610,550 | -4.55% | ||
| 2024-08-15 | Sale | PRESIDENT AND CEO | 10,000 0.0082% | $57.95 | $579,490 | 0.00% | ||
| 2024-08-14 | Sale | PRESIDENT AND CEO | 10,000 0.0081% | $57.25 | $572,471 | 0.00% | ||
| 2024-08-14 | Sale | director | 9,881 0.0081% | $57.70 | $570,134 | 0.00% | ||
| 2024-08-13 | Sale | PRESIDENT AND CEO | 10,000 0.0079% | $56.25 | $562,490 | 0.00% | ||
| 2024-08-13 | Sale | director | 10,000 0.0079% | $56.19 | $561,930 | 0.00% | ||
| 2024-08-12 | Sale | director | 10,000 0.0079% | $55.72 | $557,230 | +4.28% |
Insider Historical Profitability
| Torley Helen | PRESIDENT AND CEO | 676744 0.5319% | $49.19 | 1 | 44 | +68.25% |
| LaBarre Michael J. | SVP, CHIEF TECHNICAL OFFICER | 173756 0.1366% | $49.19 | 0 | 45 | |
| Posard Matthew L. | director | 69874 0.0549% | $49.19 | 0 | 8 | |
| LaBrosse Nicole | SVP, CHIEF FINANCIAL OFFICER | 15480 0.0122% | $49.19 | 0 | 6 | |
| Frost Gregory Ian | CEO, President | 3555331 2.7945% | $49.19 | 4 | 16 | +20.07% |
| KIRK RANDAL J | 10 percent owner | 1897610 1.4915% | $49.19 | 56 | 18 | +103.31% |
| Lim Jonathan E | President, CEO | 680000 0.5345% | $49.19 | 1 | 8 | +18.01% |
| RAMSAY DAVID A | VP and Chief Financial Officer | 323492 0.2543% | $49.19 | 7 | 3 | +24.44% |
| FALBERG KATHRYN E | director | 280000 0.2201% | $49.19 | 3 | 0 | +46.53% |
| Engler Robert | director | 273176 0.2147% | $49.19 | 5 | 3 | +18.07% |
| MATSUI CONNIE | director | 181983 0.143% | $49.19 | 0 | 2 | |
| PATTON JOHN STUART | director | 179876 0.1414% | $49.19 | 0 | 22 | |
| Kelley Kenneth J | director | 179833 0.1413% | $49.19 | 3 | 22 | +50.56% |
| Yocum Richard C | VP Clinical Development | 65975 0.0519% | $49.19 | 0 | 1 | |
| BIZZARI JEAN-PIERRE | director | 52544 0.0413% | $49.19 | 0 | 1 | |
| Henderson Jeffrey William | director | 39045 0.0307% | $49.19 | 0 | 3 | |
| Chondros Dimitrios | SVP, Chief Medical Officer | 38584 0.0303% | $49.19 | 0 | 2 | |
| Shaffer James P | VP & Chief Commercial Officer | 26300 0.0207% | $49.19 | 1 | 0 | +34.32% |
| Daly James M | director | 20503 0.0161% | $49.19 | 0 | 4 | |
| Thornton Steven T | director | 15000 0.0118% | $49.19 | 0 | 3 | |
| Shepard H. Michael | VP, Chief Scientific Officer | 13198 0.0104% | $49.19 | 0 | 1 | |
| LITTLE ROBERT J | VP, Chief Commercial Officer | 13000 0.0102% | $49.19 | 2 | 0 | <0.0001% |
| Stelzer Laurie | Chief Financial Officer | 10000 0.0079% | $49.19 | 1 | 0 | <0.0001% |
| GUSTAFSON KURT A | Vice President and CFO | 8000 0.0063% | $49.19 | 1 | 0 | |
| Kennard Don A | Vice President, Regulatory Aff | 3000 0.0024% | $49.19 | 1 | 0 | +31.79% |
Institutional Investor Ownership
| BlackRock | $742.07M | 14.33 | 18.24M | -2.09% | -$15.84M | 0.02 | |
| The Vanguard Group | $530.84M | 10.25 | 13.05M | -1.59% | -$8.55M | 0.01 | |
| State Street | $263.9M | 5.1 | 6.49M | +0.18% | +$478,152.72 | 0.01 | |
| Right Side Capital Management | $167.49M | 3.24 | 4.12M | +10.99% | +$16.58M | 3.59 | |
| Artisan Partners | $154.23M | 2.98 | 3.79M | -43.32% | -$117.88M | 0.23 | |
| AllianceBernstein | $149.15M | 2.88 | 3.67M | +5.85% | +$8.24M | 0.05 | |
| JPMorgan Chase | $131.82M | 2.55 | 3.24M | +4.74% | +$5.96M | 0.01 | |
| Geode Capital Management | $123.17M | 2.38 | 3.03M | +3.69% | +$4.38M | 0.01 | |
| Macquarie Group | $121.68M | 2.35 | 2.99M | -8.88% | -$11.86M | 0.11 | |
| Td Asset Management Inc | $103.38M | 2 | 2.54M | +28.09% | +$22.67M | 0.09 | |
| GW&K Investment Management | $89.37M | 1.73 | 2.2M | -1.33% | -$1.21M | 0.79 | |
| Invesco | $84.96M | 1.64 | 2.09M | +2.85% | +$2.35M | 0.02 | |
| Arrowmark Colorado Holdings Llc | $75.62M | 1.46 | 1.86M | +17.94% | +$11.5M | 0.19 | |
| Northern Trust | $72.89M | 1.41 | 1.79M | -9.21% | -$7.4M | 0.01 | |
| Thrivent Financial For Lutherans | $69.76M | 1.35 | 1.71M | -10.76% | -$8.41M | 0.15 | |
| Bank of America | $69.04M | 1.33 | 1.7M | +42.9% | +$20.73M | 0.01 | |
| Dimensional Fund Advisors | $68.68M | 1.33 | 1.69M | +4.66% | +$3.06M | 0.02 | |
| Charles Schwab | $67.83M | 1.31 | 1.67M | -3.95% | -$2.79M | 0.02 | |
| Nuveen | $67.19M | 1.3 | 1.65M | +8.29% | +$5.14M | 0.02 | |
| Stephens Investment Management Group LLC | $62.92M | 1.22 | 1.55M | +1.86% | +$1.15M | 0.84 | |
| Epoch Investment Partners Inc | $58.32M | 1.13 | 1.43M | +23.27% | +$11.01M | 0.26 | |
| Morgan Stanley | $55.14M | 1.07 | 1.36M | +5.8% | +$3.02M | <0.01 | |
| T. Rowe Price | $52.84M | 1.02 | 1.3M | -6.55% | -$3.7M | 0.01 | |
| BNY Mellon | $49.39M | 0.95 | 1.21M | -6.13% | -$3.23M | 0.01 | |
| First Trust | $48.59M | 0.94 | 1.19M | +1,200.58% | +$44.85M | 0.05 | |
| New York State Common Retirement Fund | $37.33M | 0.72 | 917,759 | -3.33% | -$1.28M | 0.05 | |
| Handelsbanken | $33.71M | 0.65 | 828,669 | +236.76% | +$23.7M | 0.15 | |
| Goldman Sachs | $33.41M | 0.65 | 821,386 | -46.72% | -$29.3M | 0.01 | |
| Granite Investment Partners Llc | $33.01M | 0.64 | 811,458 | -2.52% | -$852,815.51 | 1.25 | |
| LAZARD ASSET MANAGEMENT LLC | $32.79M | 0.63 | 805,975 | -10.18% | -$3.72M | 0.04 | |
| American Century Investments | $30.46M | 0.59 | 748,722 | +5.27% | +$1.52M | 0.02 | |
| Allspring Global Investments | $28.32M | 0.55 | 696,127 | -4.38% | -$1.3M | 0.05 | |
| Wells Fargo | $25.92M | 0.5 | 637,276 | -2.96% | -$789,517.91 | 0.01 | |
| Boston Partners | $25.5M | 0.5 | 630,368 | +14.12% | +$3.15M | 0.03 | |
| Silvercrest Asset Management Group Inc | $24.54M | 0.47 | 603,137 | +2% | +$480,227.40 | 0.17 | |
| Fuller & Thaler Asset Management, Inc. | $23.12M | 0.45 | 568,361 | +38.73% | +$6.46M | 0.1 | |
| Janus Henderson | $21.6M | 0.42 | 531,125 | +24.03% | +$4.19M | 0.01 | |
| Bank of Montreal | $21.18M | 0.41 | 519,430 | +2.95% | +$606,983.79 | 0.01 | |
| 2Xideas | $20.97M | 0.41 | 515,462 | -5.28% | -$1.17M | 2.57 | |
| Kennedy Capital Management Inc | $20.87M | 0.4 | 513,096 | -22.59% | -$6.09M | 0.44 | |
| Federated Hermes | $20.55M | 0.4 | 505,101 | +9.96% | +$1.86M | 0.05 | |
| Royal Bank of Canada | $19.96M | 0.39 | 490,665 | -1.81% | -$367,579.84 | 0.01 | |
| Kornitzer Capital Management Inc Ks | $19.74M | 0.38 | 485,234 | +2.21% | +$427,140.00 | 0.36 | |
| LSV Asset Management | $18.79M | 0.36 | 461,800 | -0.13% | -$24,407.97 | 0.04 | |
| Mizuho Markets Americas Llc | $18.58M | 0.36 | 456,636 | +2.23% | +$405,782.99 | 0.42 | |
| Renaissance Technologies | $17.55M | 0.34 | 431,380 | +123.07% | +$9.68M | 0.03 | |
| RhumbLine Advisers | $17.57M | 0.34 | 431,828 | +0.62% | +$108,371.35 | 0.02 | |
| Congress Asset Management Co Ma | $16.59M | 0.32 | 407,867 | +16.18% | +$2.31M | 0.12 | |
| Man Group Plc | $16.27M | 0.31 | 400,068 | +15.03% | +$2.13M | 0.04 | |
| Voloridge Investment Management, LLC | $16.2M | 0.31 | 398,306 | +627.71% | +$13.98M | 0.06 |